These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 83393)

  • 41. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
    Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
    Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human prostate steroid hormone receptor quantitation. Current methodology and possible utility as a clinical discriminant in carcinoma.
    Shain SA; Boesel RW
    Invest Urol; 1978 Nov; 16(3):169-74. PubMed ID: 361632
    [No Abstract]   [Full Text] [Related]  

  • 43. [Determination of angiotensin converting enzyme in prostate diseases].
    Van Camp K; Van Sande M; Neels H
    Verh K Acad Geneeskd Belg; 1985; 47(4):287-302. PubMed ID: 2417428
    [No Abstract]   [Full Text] [Related]  

  • 44. Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases.
    Gagnon S; Têtu B; Dubé JY; Tremblay RR
    Am J Pathol; 1990 May; 136(5):1147-52. PubMed ID: 2349965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cambial (stem)-zone and microcarcinoma: immunohistochemical and morphometric study approach.
    Battaglia S; Nigrisoli E; Botticelli AR; Barbolini G
    Appl Pathol; 1985; 3(4):255-61. PubMed ID: 2430599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of prostatic fluid in prostatic pathology.
    Grayhack JT; Lee C
    Prog Clin Biol Res; 1981; 75A():231-46. PubMed ID: 6175976
    [No Abstract]   [Full Text] [Related]  

  • 47. [Steroid hormone receptors in malignant neoplasms of the human prostate gland].
    Bassalyk LS; Kushlinskiĭ NE
    Vestn Akad Med Nauk SSSR; 1984; (10):82-8. PubMed ID: 6506859
    [No Abstract]   [Full Text] [Related]  

  • 48. Metachromasia in the human prostate: a histochemical difference between benign prostatic hyperplasia and prostatic carcinoma.
    Arcadi JA
    J Urol; 1988 Feb; 139(2):315-7. PubMed ID: 2448498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leucine-arylamidase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
    Verlooy J; van Sande M; Van Camp K
    Acta Urol Belg; 1981 Oct; 49(4):491-5. PubMed ID: 6172970
    [No Abstract]   [Full Text] [Related]  

  • 50. Monodispersal and deoxyribonucleic acid analysis of prostatic cell nuclei.
    Goerttler K; Ehemann V; Tschahargane C; Stoehr M
    J Histochem Cytochem; 1977 Jul; 25(7):560-4. PubMed ID: 70447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide hormones, serotonin, and other cell differentiation markers in benign hyperplasia and in carcinoma of the prostate.
    Abrahamsson PA; Alumets J; Wadström LB; Falkmer S; Grimelius L
    Prog Clin Biol Res; 1987; 243A():489-502. PubMed ID: 2443920
    [No Abstract]   [Full Text] [Related]  

  • 52. Aldolase activity in benign prostatic hypertrophy and adenocarcinomatous prostate.
    Verlooy J; van Sande M; Van Camp K
    Acta Urol Belg; 1980 Jan; 48(1):65-7. PubMed ID: 6159782
    [No Abstract]   [Full Text] [Related]  

  • 53. Lectin binding to prostatic adenocarcinoma.
    Söderström KO
    Cancer; 1987 Oct; 60(8):1823-31. PubMed ID: 2443233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simian-sarcoma-virus-related sequences in DNAs from human prostatic tissues.
    Arya SK
    Oncology; 1980; 37(2):83-8. PubMed ID: 6153784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
    Hussein MR; Al-Assiri M; Musalam AO
    Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of ras oncogene p21 in prostate cancer.
    Viola MV; Fromowitz F; Oravez S; Deb S; Finkel G; Lundy J; Hand P; Thor A; Schlom J
    N Engl J Med; 1986 Jan; 314(3):133-7. PubMed ID: 2417118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Importance of determining steroid hormone receptors and the treatment of prostatic cancer].
    Fedotov IA; Denisov LE; Kozlov VP; Degtiar' VG
    Urol Nefrol (Mosk); 1983; (1):63-70. PubMed ID: 6187115
    [No Abstract]   [Full Text] [Related]  

  • 58. The immunocytochemical detection of growth hormone and prolactin in human prostatic tissues.
    Harper ME; Sibley PE; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1981; 75B():115-28. PubMed ID: 6172800
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantitative analysis of epidermal growth factor in human benign prostatic hyperplasia and prostatic carcinoma and its prognostic significance.
    Shaikh N; Lai L; McLoughlin J; Clark D; Williams G
    Anticancer Res; 1990; 10(4):873-4. PubMed ID: 1696447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.